# Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

> **NCT01910480** · PHASE1 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 24 (actual)

## Conditions studied

- Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

## Interventions

- **DRUG:** NBI-98854 50 mg capsule once daily
- **DRUG:** Ketoconazole 400 mg (200 mg twice daily)

## Key facts

- **NCT ID:** NCT01910480
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910480, "Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01910480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*